New Study Supports Assay for Guiding Kidney Transplant Rejection Treatment

A recent study published in The Lancet Regional Health – Europe highlights the potential of the iMDx GraftAssure assay, utilizing donor-derived cell-free DNA monitoring, to inform treatment decisions for kidney transplant patients experiencing organ rejection. This research builds upon earlier findings, suggesting that prolonged, dd-cfDNA-guided therapy can be both safe and effective for achieving long-term success in preventing allograft failure. The findings offer a promising approach to personalize and improve post-transplant care.